To study the characteristics and outcomes of cancer patients with coronavirus (Covid 19) admitted to the intensive care unit in a Cancer Centre
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: C00-D49- Neoplasms
- Registration Number
- CTRI/2021/06/034301
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All adult patients >18 years diagnosed with Covid-19 admitted to the Intensive Care unit in TMH
Exclusion Criteria
Post Bone Marrow transplant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality in the ICU for cancer patients with covid-19Timepoint: At 30 day
- Secondary Outcome Measures
Name Time Method In-hospital mortality and 30-day mortality for cancer patients with covid-19Timepoint: At 30 day <br/ ><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link SARS-CoV-2 infection to worsened outcomes in oncology ICU patients?
How do standard-of-care antiviral therapies compare in efficacy for cancer patients with severe COVID-19?
Which biomarkers correlate with ICU mortality in neoplastic patients co-infected with SARS-CoV-2?
What adverse event profiles are observed in cancer patients receiving dexamethasone for COVID-19 in ICUs?
How do combination therapies like remdesivir plus tocilizumab perform in hematologic vs. solid tumor ICU cohorts?